Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 14/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 12/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174025 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C19PSMB8PSMB5 | |
| SCHEMBL4176649 | 0.86 | PSMB8 (0.43) | ALDH1A1CYP3A4CYP2C19PSMB8PSMB5 | |
| SCHEMBL4176652 | 0.86 | PSMB8 (0.43) | ALDH1A1CYP3A4CYP2C19PSMB8PSMB5 | |
| SCHEMBL4174786 | 0.84 | TDP1 (0.47) | ALDH1A1CYP3A4CYP2C19PSMB8PSMB5 | |
| SCHEMBL4172106 | 0.83 | TDP1 (0.54) | ALDH1A1CYP3A4CYP2C19PSMB8PSMB5 | |
| SCHEMBL4177606 | 0.80 | PSMB8 (0.48) | PSMB8PSMB5 | |
| SCHEMBL4177600 | 0.80 | PSMB8 (0.48) | PSMB8PSMB5 | |
| SCHEMBL22500322 | 0.74 | KMT2A (0.66) | ALDH1A1TSHR | |
| SCHEMBL29272845 | 0.74 | KMT2A (0.66) | ALDH1A1TSHR | |
| SCHEMBL20052441 | 0.74 | MMP9 (0.44) | ALDH1A1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | ALDH1A1 2655/4885CYP3A4 2311/4885CYP2C19 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.